Engineered EV-mediated delivery of an anti-amyloid peptide provides neuroprotection in an in vitro Alzheimer's disease model.
Peptide delivery just got a serious upgrade. Researchers in India engineered extracellular vesicles (EVs) to shuttle an anti-amyloid peptide directly to neurons, showing real neuroprotection in an in vitro Alzheimer’s disease model. Alzheimer’s is notorious for amyloid-β clumps, oxidative stress, and the slow breakdown of brain cells. Getting peptides into neurons has always been the bottleneck. These scientists tackled it head-on.
Int J Pharm
by Singh VB, Gupta S, Sella RN
“Engineered EV-mediated delivery of an anti-amyloid peptide provides neuroprotection in an in vitro Alzheimer's disease model. Singh VB(1), Gupta S(2), Sella RN(3). Author information: (1)Membrane-Protein Interaction Laboratory, Department of Genetic Engineering, School of Bioengineering, College of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India. (2)Neurodegeneration and Peptide Engineering Research Lab, Biological Engineering Discipline, Indian Institute of Technology Gandhinagar, Gujarat 382355, India. (3)Membrane-Protein Interaction Laboratory, Department of Genetic Engineering, School of Bioengineering, College of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India. Electronic address: raja.clri@gmail.com. Alzheimer's disease is driven in part by amyloid-β (Aβ) aggregation, oxidative stress, and progressive neuronal dysfunction. Despite various attempts, therapeutic translation remains limited by inefficient delivery of bioactive molecules to neuronal cells. This study presents a surface-engineered extracellular vesicle (EV) platform designed for targeted peptide delivery, assessing its neuroprotective efficacy in an in vitro model of Alzheimer's disease. EVs were obtained from NIH/3T3 cells expressing Lamp2b-RVG and were surface-modified with the β-sheet breaker peptide H102 through CP05-CD63 affinity binding. ATR-FTIR, SERS Raman spectroscopy, high-resolution transmission electron microscopy, nanoparticle tracking analysis, zeta potential measurements, and EV marker profiling demonstrated successful peptide conjugation and vesicle integrity. Aggregated Aβ25-35 was utilized to assess neuronal toxicity in NGF-differentiated PC-12 cells. Peptide-modified EV demonstrated effective, time-dependent cellular uptake and significantly improved cell viability while decreasing membrane damage and intracellular reactive oxygen species levels in comparison to Aβ-treated controls. Treatment with Peptide-modified EV normalized the expression of key genes associated with Alzheimer's, such as APP, Bax, Sirt1, and Stat1, suggesting a coordinated modulation of amyloidogenic, apoptotic, oxidative, and inflammatory pathways. The results indicate that surface-engineered EVs facilitate efficient neuronal delivery of therapeutic peptides and offer multi-level cytoprotection against Aβ-induced neurotoxicity. This study emphasizes the capability of peptide-decorated EV as a multifunctional nanocarrier system for the treatment of Alzheimer's disease. Copyright © 2026. Published by Elsevier B.V. Conflict of interest statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.”
They built their EVs from NIH/3T3 cells, modified to express Lamp2b-RVG for brain targeting. Then they loaded the vesicle surface with H102, a β-sheet breaker peptide, using a precise affinity-binding trick. The team ran the full gauntlet of characterization—spectroscopy, electron microscopy, nanoparticle tracking, and more—to confirm the vesicles were stable and the peptide was stuck right where it should be.
The real test: could these EVs protect neurons from amyloid-β toxicity? Researchers used NGF-differentiated PC-12 cells and hit them with aggregated Aβ25-35 to mimic Alzheimer’s stress. Key findings:
Peptide-loaded EVs were rapidly and efficiently taken up by neurons
Cells treated with these EVs had higher survival rates and less membrane damage
Markers of oxidative stress dropped significantly compared to amyloid-only controls
Expression of Alzheimer’s-related genes (APP, Bax, Sirt1, Stat1) was normalized
Key takeaway: surface-engineered EVs deliver anti-amyloid peptides straight to neurons, protecting them at multiple biological levels. This isn’t just a delivery trick—it’s coordinated defense against amyloid toxicity, oxidative stress, and gene expression changes all at once.
For anyone tracking the future of targeted neurotherapeutics or advanced peptide research, this is a proof-of-concept worth following. Peptide-decorated EVs are shaping up as serious contenders in the fight against neurodegenerative diseases. The potential for new research tools and platforms is wide open.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.